135 related articles for article (PubMed ID: 33049114)
1. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
Wessels AM; Lines C; Stern RA; Kost J; Voss T; Mozley LH; Furtek C; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; Dupre N; Randolph C; Michelson D; Andersen SW; Shering C; Sims JR; Egan MF
Alzheimers Dement; 2020 Nov; 16(11):1483-1492. PubMed ID: 33049114
[TBL] [Abstract][Full Text] [Related]
2. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
3. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
[TBL] [Abstract][Full Text] [Related]
4. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
[TBL] [Abstract][Full Text] [Related]
6. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
Doggrell SA
Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
[No Abstract] [Full Text] [Related]
7. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
[TBL] [Abstract][Full Text] [Related]
8. Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy.
Sergott RC; Raji A; Kost J; Sur C; Jackson S; Locco A; Patel A; Furtek C; Mattson B; Egan MF
J Alzheimers Dis; 2021; 79(1):275-287. PubMed ID: 33252075
[TBL] [Abstract][Full Text] [Related]
9. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
[TBL] [Abstract][Full Text] [Related]
10. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.
Querol-Vilaseca M; Sirisi S; Molina-Porcel L; Molina B; Pegueroles J; Ferrer-Raventós P; Nuñez-Llaves R; Dols-Icardo O; Balasa M; Iulita MF; Blesa R; Belbin O; Clarimon J; Fortea J; Gelpi E; Sánchez-Valle R; Lleó A
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12781. PubMed ID: 34825396
[TBL] [Abstract][Full Text] [Related]
11. Merck ends trial of potential Alzheimer's drug verubecestat.
Hawkes N
BMJ; 2017 Feb; 356():j845. PubMed ID: 28202490
[No Abstract] [Full Text] [Related]
12. Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions.
Voss T; Kost J; Mercer SP; Furtek C; Randolph C; Lines C; Egan MF; Cummings JL
J Alzheimers Dis; 2023; 92(1):341-348. PubMed ID: 36744336
[TBL] [Abstract][Full Text] [Related]
13. β-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?
Selkoe D
Lancet Neurol; 2019 Jul; 18(7):624-626. PubMed ID: 31202466
[No Abstract] [Full Text] [Related]
14. Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.
Evin G
BioDrugs; 2016 Jun; 30(3):173-94. PubMed ID: 27023706
[TBL] [Abstract][Full Text] [Related]
15. Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).
Sims JR; Selzler KJ; Downing AM; Willis BA; Aluise CD; Zimmer J; Bragg S; Andersen S; Ayan-Oshodi M; Liffick E; Eads J; Wessels AM; Monk S; Schumi J; Mullen J
J Prev Alzheimers Dis; 2017; 4(4):247-254. PubMed ID: 29181490
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
[TBL] [Abstract][Full Text] [Related]
17. BACE inhibitors in clinical development for the treatment of Alzheimer's disease.
Panza F; Lozupone M; Solfrizzi V; Sardone R; Piccininni C; Dibello V; Stallone R; Giannelli G; Bellomo A; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
Expert Rev Neurother; 2018 Nov; 18(11):847-857. PubMed ID: 30277096
[TBL] [Abstract][Full Text] [Related]
18. BACE inhibitor bust in Alzheimer trial.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
[No Abstract] [Full Text] [Related]
19. Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
Qu L; Ji L; Wang C; Luo H; Li S; Peng W; Yin F; Lu D; Liu X; Kong L; Wang X
Eur J Med Chem; 2021 Jul; 219():113441. PubMed ID: 33862517
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
